Here's Why NextCure Stock Blew Through the Roof Today
Shares of NextCure (NASDAQ: NXTC), a clinical-stage biopharmaceutical company developing new cancer drugs, exploded higher this morning. Updated clinical trial results from a handful of non-small cell lung cancer patients sent the biotech stock 225.8% higher as of 3:22 p.m. EST on Tuesday.
NextCure made its stock-market debut in May. At the moment, a Siglec-15 (S15) antibody called NC318 is its only new drug candidate in clinical-stage testing.
Image source: Getty Images.
Source Fool.com
